Introduction
A close relationship between human T-lymphotropic virus type I (HTLV-I) and chronic myelopathy was reported in 1985 and 1986 (1, 2) . Since then numerous studies on HTLV-Iinfected subjects have been reported (3), and many case reports on HTLV-I associated with autoimmune disorders have suggested that HTLV-I infection can lead to autoimmune disorders (4) (5) (6) (7) (8) . Some investigators (9-1 1 ) reported high levels of serum immunoglobulin (Ig) in HTLV-I infected subjects, but to our knowledge, no one has studied the prevalence ofautoantibodies a mong persons infected with HTLV-I.
Serum levels of gammaglobulin and immunoglobulin (Ig) increase with age (12, 13); various types of autoantibodies are detected in patients without collagen diseases and even in healthy people, and the prevalence of such autoantibodies increases with age (12, (14) (15) (16) .
Recently, an increase with radiation dose was reported in the prevalence of rheumatoid factor (RF) and IgM serum level among atomic bomb survivors (17) .
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Humoral Immunity in HTLV-I Carriers jects from this earlier study population available at the time of the biennial examination in 1992, and we re-examined the anti-HTLV-I antibody titers using the gelatin-particle-agglutination method. The results were similar to previous determinations except for five subjects.
For these five subjects, therefore, we used the results obtained by the gelatin-particle-agglutination method in the present study. Among the above 289 subjects, five had not been exposed to atomic bomb radiation and 76 had no DS86
estimates. The ANAwas assayed by the indirect immunofluorescence technique using HEp-2 cells (Fujirebio, Tokyo) as a nuclear substrate. The titer was measured by the two-fold dilution method, with a maximum titer of 1:40 or more considered positive. The immunofluorescent patterns were classified into five groups, i.e. , homogeneous, speckled, nucleolar, peripheral, and discretely speckled. The RF and anti-Tg were both measured by the indirect agglutination method using commercial assay kits (Fujirebio).
The RF titer was measured by the twofold dilution method, with a maximum titer of 1:40 or more considered positive. The anti-Tg titer was measured by the fourfold dilution method, with a maximum titer of 1: 100 or more c onsidered positive.
The serum levels ofIgG, IgA, andIgM were measuredby the turbidimetric immunoassay method using an autoanalyzer (Hitachi 7050, Tokyo).
Except for the ANA which was assayed by a commercial laboratory called SRL (Tokyo, Japan), all of the assays were conducted in our laboratory.
Statistical analyses
Wecompared the serum level of IgG, IgA, andIgM in two groups, i.e.,the HTLV-I-seropositive andseronegative groups, using the analysis of covarianceto adjust the serum levels for sex, ageandradiation dose. Weused the base-10 logarithm of the databecause the distributions of the serum levels were all approximately log-normal. Theprevalenceof the three antibodies wasanalyzed using logisticregressionmodelsincluding sex, age, radiation dose andHTLV-I as covariates.Thecalculations were all performed with programs 4V and LR of BMDP (22) .
Results
A breakdownof the subjects is shownin Table 1 . No individuals with collagen diseases (systemic lupus erythematosus, polyarteritis nodosa, polymyositis or dermatomyositis, progressive systemic sclerosis, rheumatoidarthritis, rheumatic fever), HAM, or adult Tences were observedbetv egative subjects in sex ra
The meanserumlev seropositivei subjects th, cell leukemia were found. No differeen HTLV-I-seropositive and seronio, age distribution, or radiation dose, il of IgM was higher in HTLV-In in HTLV-I-seronegative subjects radiation dose. There wa: HTLV-I or sex, however! The proportion of sui among HTLV-I-seropositive subjects than HTLV-I-seronegative subjects, while the proportion of persons with ANAwas smaller among those HTLV-I-seropositive (Table 3 ). The logistic regression analyses indicated that the prevalence of RF was associated with radiation dose, sex and age but not with HTLV-Iand that although the increase with radiation dose was significant (p = 0.03), neither the increase with age nor the higher prevalence in female subjects were statistically significant (p = 0.17 and 0.15, respectively). No association with radiation dose, sex, age or HTLV-Iwas indicated for the As shown in Table 4 , the ANA titers in most subjects did not exceed 1
:80, and more than half of the ANA staining patterns were homogeneous or speckled. No significant difference was observed between the HTLV-I-seropositive and seronegative subjects with respect to ANA titer or staining pattern. The proportion of subjects with high RF titer (>1 : 160) and high antiTg titer (>1: 1,600) were 9/23 (2/8 and 7/15 in HTLV-I-seropositive and seronegative subjects) and 7/17 (3/7 and 4/10 in HTLV-I-seropositive and seronegative subjects), respectively, and no significant difference was observed between the HTLV-I-seropositive and seronegative subjects with respect to either RF or anti-Tg titers.
Discussion
The subjects were AHS members examined during a certain period in 1992, and HTLV-I-seropositive subjects were selected more extensively than HTLV-I-seronegative subjects from the early study population: the respective sampling fractions were 59/262 (22.5%) and 149/2,785 (5.4%). The sampling was thus not random, but no differences were observed between HTLV-I-seropositive and seronegative subjects with regard to sex ratio, age distribution or radiation dose. We therefore consider that the sampling procedure did not affect the results of the present study. The high prevalence of ANA shown in Table 3 may raise questions about the assay and point to potential biases such as inclusion of patients with common disorders and radiation exposure. The laboratory SRL assayed ANA among 1) 148 healthy workers aged from 24 to 47 years, and 2) 41 1 healthy men aged from their 2G's to 70's (mean age 47.3 years) and 593 healthy women aged from their 30's to 70's (mean age 49.7 years). As a result, the ANA titer was less than 1:40 in 143 (95.6%) of the healthy workers, 406 (98.8%) of the healthy men and 530 (89.4%) of the healthy women. These data suggest the high specificity of the assay. The prevalence of ANA by radiation exposure (shielded kerma dose in Gy) group was as follows: 48.9% in 0 Gy group, 67.7% in 0.01-0.49 Gy group, 35.5% in 0.50-0.99 Gy group and46.3% in 1.0-Gy group. Thus no association with radiation exposure was observed in the prevalence of ANA. We reviewed the medical records of the study subjects and found that 191 of the 208 study subjects had participated in the Nagasaki Thyroid Program between October 1984 and April 1987 (23) . Antimicrosomal antibody and antithyroglobulin antibody levels were assayed in all participants. Among the 191 study subjects who had participated in the program, 146had no antithyroid antibodies or thyroid diseases. The prevalence ofANA, RF and anti-Tg in the 146 subjects was 47.3%, 1 1.6% and 4.8%, respectively, which are close to those shown in Table 3 . As shown in Table 4 , the ANA titers in 75 (36.1%) of the 208 subjects were 1:40; similarly, 49 (33.6%) of the 146 subjects had ANA titers of 1:40. We therefore reanalyzed the data using a cut-off of 1:80, but, except for the prevalence of ANA, no significant change was observed in the results. Since we have no more data to change the cut-off of 1 :40 set by SRL, we used this cut-off in the analysis of our data.
Among the few previous studies on serum levels of Ig in HTLV-I-infected subjects, Morishima et al (9) reported that serum IgG level was significantly higher in HTLV-I-seropositive subjects without adult T-cell leukemia than in HTLV-Iseronegative subjects but that the IgA and IgM serum levels were the same in the two groups. Previous investigations (10, 1 1) also failed to show a higher serum level ofIgM in HTLV-I-seropositive subjects than in HTLV-I-seronegative subjects.
In the present study, however, the mean IgM serum level was significantly higher in HTLV-I-seropositive subjects than in HTLV-I-seronegative subjects, although the mean IgA serum level did not differ in the two groups after adjustment for age and radiation dose. The disagreement between these studies may be due partly to sample size and characteristics of the study subjects. The sample used in the present study, including controls, is larger than the samples in previous studies. All of the subjects in the present study were atomic bomb survivors over 45 years of age, and persons with common disorders such as hypertension, diabetes mellitus, chronic liver disease and chronic thyroiditis were included.
In previous studies, "healthy subjects" were used as controls, but the definition of"healthy" was not specified.
Wecould find no report showing a high IgM serum level in patients with persistent viral infection. However, the IgM serum level increases along with viral-specific IgM antibody in the early stages of viral infection.
Nagasato et al (24, 25) stated that IgM antibody against HTLV-I is frequently detected in the serum of HAM patients and HTLV-I-seropositive subjects and that this indicates persistent active replication of HTLV-I.
Therefore, the high IgM serum levels in HTLV-I-infected subjects in the current study may indicate persistent active viral replication.
As mentioned above, autoantibodies such as ANA, RF, and anti-Tg are detected in patients with noncollagen diseases and even in healthy individuals.
The prevalence of autoantibodies varies among investigations because of differences in the diagnostic methods and reagents employed (26) (27) (28) .
For this reason prevalence or positive rate of autoantibodies in various studies is difficult to compare. In view of this fact, we implemented a large number of HTLV-I-seronegative subjects as controls. However, our results revealed a lower ANA prevalence in HTLV-I-seropositive subjects than in HTLV-I-seronegative subjects, although the difference was not statistically significant (p = 0.08). Eguchi et al (29) reported that the positive rate of ANA was no higher in HTLV-I-seropositive patients with Sjogren's syndrome than in HTLV-I-seronegative patients with Sjogren' s syndrome. Further examinations for ANA subclass such as anti-DNA antibody and anti-centromere antibody are required to determine the difference between these two groups.
A significant increase in RF prevalence with radiation dose was found: exposure to 1 Gy was estimated to increase the prevalence by 1.6 (95% confidence interval:
However, no significant difference in the RF prevalence was observed between HTLV-I-seropositive and seronegative subjects. In this study, we employed the indirect agglutination method using artificial gelatin-particle carrier sensitized with denatured rabbit IgG to detect RF, that is, to detect mainly IgMtype RF. IgM-type RF results from stimulation by various antigens (30). We, however, have no data to interpret the s ignificant increase of the RF prevalence with radiation dose.
The results of the present study suggest humoral immunity differences between HTLV-I-infected and noninfected subjects, but whether HTLV-I infection can lead to autoimmune disorders remains uncertain. 
